Abstract 46P
Background
Lenvatinib has been identified as a multikinase inhibitor with the effect of inhibiting angiogenesis for advanced ICC. This study aimed to compare the efficacy and safety of GEMOX and PD-1 inhibitors combined with or without lenvatinib as first-line therapy for advanced ICC.
Methods
Eligible participants with treatment naive and diagnosis of unresectable advanced ICC were assigned to G-P-L group: gemcitabine (1000 mg/m2on days 1 and 8 every 3 weeks), oxaliplatin (85 mg/m2on day 1 every 3 weeks), PD-1 inhibitors and lenvatinib (12 mg for weight ≥ 60 kg or 8 mg for weight < 60 kg, once daily), and G-P group: gemcitabine, oxaliplatin and PD-1 inhibitors. The primary endpoints was to assess objective response rate (ORR) evaluated with mRECIST 1.1 and adverse events (AEs). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Genetic mutation biomarkers for lenvatinib were explored using WES.
Results
77 patients were enrolled and divided into G-P-L group (n=38) and G-P group (n=39). The median follow-up time was 23 months. The median PFS were 13 months in the G-P-L group and 7.9 months in the G-P group (hazard ratio[HR]: 0.38, 95% CI: 0.20–0.71, P=0.007). The median OS were 18.5 months in the G-P-L group and 14.6 months in the G-P group (P=0.19). No significant differences of grade ≥ 3 AEs were found between the G-P-L group and the G-P group (68.4% and 64.1%). ORR, DCR were 39.5% and 89.5% in the G-P-L group versus 33.3% and 76.9% in the G-P group, respectively. Multivariate Cox regression analysis indicated that with or without Lenvatinib combination was the independent risk factor of PFS in the entire group (P=0.002). Keap-1 gene mutation was found with significant difference in PR group comparing with SD and PD group in the G-P-L group (P=0.003).
Conclusions
GEMOX combined with PD-1 inhibitor and lenvatinib indicated the feasibility as first-line therapy for advanced ICC with Keap-1 gene mutation. Multi-center with large scale of cases study were needed for further exploration.
Clinical trial identification
NCT05215665.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
55P - Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
Presenter: Arndt Vogel
Session: Poster session 13
56P - Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
Presenter: Federico Nichetti
Session: Poster session 13
57P - Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer
Presenter: Pietro Carotenuto
Session: Poster session 13
58P - Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
Presenter: Changhoon Yoo
Session: Poster session 13
59P - Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
Presenter: Gael Roth
Session: Poster session 13
60P - Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
Presenter: Lorenza Rimassa
Session: Poster session 13
61P - Addressing racial disparities in clinical trials in cholangiocarcinoma
Presenter: Abhinav Vyas
Session: Poster session 13
Resources:
Abstract
62TiP - HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
Presenter: Teresa Macarulla Mercade
Session: Poster session 13
240P - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Presenter: Michael Untch
Session: Poster session 13